Redmile Group, LLC - Q3 2017 holdings

$2.03 Billion is the total value of Redmile Group, LLC's 65 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 45.3% .

 Value Shares↓ Weighting
ARRY BuyARRAY BIOPHARMA INC$215,946,000
+60.3%
17,556,586
+9.1%
10.65%
+29.9%
FOLD SellAMICUS THERAPEUTICS INC$166,069,000
+36.9%
11,012,561
-8.6%
8.19%
+11.0%
PBYI BuyPUMA BIOTECHNOLOGY INC$108,570,000
+44.4%
906,642
+5.4%
5.36%
+17.0%
SGEN BuySEATTLE GENETICS INC$100,318,000
+191.5%
1,843,733
+177.2%
4.95%
+136.2%
CLVS BuyCLOVIS ONCOLOGY INC$82,121,000
+14.7%
996,610
+30.4%
4.05%
-7.0%
ALDR BuyALDER BIOPHARMACEUTICALS INC$79,340,000
+211.6%
6,476,766
+191.2%
3.91%
+152.5%
AZN NewASTRAZENECA PLCsponsored adr$76,105,0002,246,300
+100.0%
3.75%
INSM BuyINSMED INC$62,159,000
+29220.3%
1,991,646
+15987.6%
3.07%
+23484.6%
IMGN BuyIMMUNOGEN INC$61,670,000
+66.4%
8,061,497
+54.7%
3.04%
+34.8%
RGNX SellREGENXBIO INC$54,950,000
+61.9%
1,667,672
-3.0%
2.71%
+31.2%
PEN SellPENUMBRA INC$51,066,000
-37.5%
565,511
-39.3%
2.52%
-49.4%
WVE BuyWAVE LIFE SCIENCES LTD$49,323,000
+19.2%
2,267,707
+1.9%
2.43%
-3.4%
ATRA BuyATARA BIOTHERAPEUTICS INC$47,825,000
+24.9%
2,889,710
+5.7%
2.36%
+1.2%
LIVN BuyLIVANOVA PLC$44,312,000
+241.4%
632,488
+198.3%
2.19%
+176.7%
CNC BuyCENTENE CORP DEL$39,153,000
+23.1%
404,600
+1.6%
1.93%
-0.3%
ICUI BuyICU MED INC$37,495,000
+64.0%
201,750
+52.3%
1.85%
+33.0%
AET NewAETNA INC NEW$37,182,000233,837
+100.0%
1.83%
BOLD SellAUDENTES THERAPEUTICS INC$36,114,000
+29.3%
1,289,332
-11.7%
1.78%
+4.8%
OXFD SellOXFORD IMMUNOTEC GLOBAL PLC$34,465,000
-5.0%
2,051,487
-4.8%
1.70%
-23.0%
GWPH SellGW PHARMACEUTICALS PLCads$34,358,000
-23.0%
338,536
-23.9%
1.70%
-37.6%
 ARRAY BIOPHARMA INCnote 3.000% 6/0$34,266,000
+33.6%
19,000,0000.0%1.69%
+8.2%
EHTH BuyEHEALTH INC$31,956,000
+38.9%
1,337,623
+9.3%
1.58%
+12.6%
MOH SellMOLINA HEALTHCARE INC$31,703,000
-44.7%
461,074
-44.4%
1.56%
-55.2%
PRAH NewPRA HEALTH SCIENCES INC$30,621,000402,014
+100.0%
1.51%
ELGX BuyENDOLOGIX INC$29,189,000
-5.7%
6,544,676
+2.8%
1.44%
-23.6%
NITE NewNIGHTSTAR THERAPEUTICS PLCadr$28,839,0001,769,346
+100.0%
1.42%
VRTX BuyVERTEX PHARMACEUTICALS INC$28,737,000
+54.4%
189,008
+30.9%
1.42%
+25.2%
IRTC BuyIRHYTHM TECHNOLOGIES INC$28,640,000
+41.5%
552,041
+15.9%
1.41%
+14.7%
XNCR BuyXENCOR INC$27,511,000
+9.7%
1,200,294
+1.1%
1.36%
-11.1%
LJPC BuyLA JOLLA PHARMACEUTICAL CO$25,157,000
+18.5%
723,330
+1.4%
1.24%
-4.0%
EPZM NewEPIZYME INC$23,051,0001,210,000
+100.0%
1.14%
CMRX BuyCHIMERIX INC$22,184,000
-3.3%
4,225,575
+0.4%
1.09%
-21.6%
DPLO NewDIPLOMAT PHARMACY INC$19,823,000957,155
+100.0%
0.98%
NVTA BuyINVITAE CORP$19,792,000
+154.9%
2,112,240
+160.1%
0.98%
+106.3%
BSX SellBOSTON SCIENTIFIC CORP$17,604,000
-42.0%
603,493
-44.9%
0.87%
-53.0%
GLYC BuyGLYCOMIMETICS INC$16,985,000
+153.8%
1,214,088
+102.5%
0.84%
+105.9%
MEDP BuyMEDPACE HLDGS INC$15,939,000
+144.2%
499,640
+122.0%
0.79%
+98.0%
AMED BuyAMEDISYS INC$15,873,000
+7422.7%
283,648
+8352.0%
0.78%
+5923.1%
JNCE SellJOUNCE THERAPEUTICS INC$14,888,000
-6.8%
955,598
-16.1%
0.73%
-24.5%
INCR SellINC RESH HLDGS INCcl a$14,012,000
-71.5%
267,918
-68.2%
0.69%
-76.9%
CBAY NewCYMABAY THERAPEUTICS INC$13,276,0001,647,100
+100.0%
0.66%
NLNK NewNEWLINK GENETICS CORP$12,712,0001,248,700
+100.0%
0.63%
MODN SellMODEL N INC$12,542,000
+9.9%
838,914
-2.3%
0.62%
-10.9%
DCPH NewDECIPHERA PHARMACEUTICALS IN$11,957,000722,880
+100.0%
0.59%
LIFE NewATYR PHARMA INC$9,528,0001,886,792
+100.0%
0.47%
SYRS SellSYROS PHARMACEUTICALS INC$9,442,000
-39.7%
641,419
-34.1%
0.47%
-51.1%
CASC SellCASCADIAN THERAPEUTICS INC$8,057,000
-41.9%
1,969,969
-47.3%
0.40%
-53.0%
PRQR BuyPROQR THRAPEUTICS N V$7,774,000
-6.3%
1,602,975
+0.4%
0.38%
-24.2%
TFX NewTELEFLEX INC$7,589,00031,365
+100.0%
0.37%
CTMX SellCYTOMX THERAPEUTICS INC$6,946,000
-35.8%
382,271
-45.3%
0.34%
-48.0%
PETQ NewPETIQ INC$6,682,000246,743
+100.0%
0.33%
CTLT BuyCATALENT INC$5,895,000
+15.1%
147,663
+1.2%
0.29%
-6.7%
FATE  FATE THERAPEUTICS INC$5,619,000
+22.2%
1,419,0580.0%0.28%
-1.1%
OVID BuyOVID THERAPEUTICS INC$3,771,000
-11.0%
451,182
+0.5%
0.19%
-27.9%
SellNEURODERM LTD$2,985,000
-82.0%
76,729
-86.2%
0.15%
-85.4%
ACRS BuyACLARIS THERAPEUTICS INC$2,606,000
+1.6%
100,960
+6.8%
0.13%
-17.3%
AUPH  AURINIA PHARMACEUTICALS INC$2,084,000
+2.3%
332,3100.0%0.10%
-16.9%
HOLX NewHOLOGIC INC$734,00020,000
+100.0%
0.04%
NBIX  NEUROCRINE BIOSCIENCES INC$407,000
+33.4%
6,6400.0%0.02%
+5.3%
UNH  UNITEDHEALTH GROUP INC$356,000
+5.6%
1,8200.0%0.02%
-14.3%
NKTR  NEKTAR THERAPEUTICS$350,000
+22.8%
14,5800.0%0.02%0.0%
LHCG NewLHC GROUP INC$235,0003,310
+100.0%
0.01%
SHPG NewSHIRE PLCsponsored adr$208,0001,360
+100.0%
0.01%
ADVM  ADVERUM BIOTECHNOLOGIES INC$81,000
+44.6%
22,2360.0%0.00%
+33.3%
CSLT  CASTLIGHT HEALTH INCcl b$44,000
+4.8%
10,2290.0%0.00%
-33.3%
BKD ExitBROOKDALE SR LIVING INC$0-12,110
-100.0%
-0.01%
AGN ExitALLERGAN PLC$0-1,200
-100.0%
-0.02%
ExitPUMA BIOTECHNOLOGY INCcall$0-101,500
-100.0%
-0.54%
CLVS ExitCLOVIS ONCOLOGY INCcall$0-152,000
-100.0%
-0.87%
NSTG ExitNANOSTRING TECHNOLOGIES INC$0-866,819
-100.0%
-0.87%
NXTM ExitNXSTAGE MEDICAL INC$0-657,356
-100.0%
-1.00%
GBT ExitGLOBAL BLOOD THERAPEUTICS IN$0-631,283
-100.0%
-1.05%
BPMC ExitBLUEPRINT MEDICINES CORP$0-367,537
-100.0%
-1.13%
SPNC ExitSPECTRANETICS CORP$0-634,802
-100.0%
-1.48%
EW ExitEDWARDS LIFESCIENCES CORP$0-218,000
-100.0%
-1.57%
PRTA ExitPROTHENA CORP PLC$0-509,698
-100.0%
-1.68%
AGIO ExitAGIOS PHARMACEUTICALS INC$0-681,165
-100.0%
-2.13%
ANTM ExitANTHEM INC$0-231,886
-100.0%
-2.66%
JUNO ExitJUNO THERAPEUTICS INC$0-2,219,616
-100.0%
-4.04%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2017-11-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC43Q3 202310.1%
ATARA BIOTHERAPEUTICS INC36Q3 20236.4%
FATE THERAPEUTICS INC34Q3 202317.2%
INVITAE CORP32Q3 20232.7%
REGENXBIO INC28Q3 20233.8%
CLOVIS ONCOLOGY INC27Q1 20206.7%
IMMUNOGEN INC27Q3 202313.2%
CASTLIGHT HEALTH INC SAN FRAN COM STK27Q1 20212.5%
ARRAY BIOPHARMA INC26Q2 201912.6%
DECIPHERA PHARMACEUTICALS IN25Q3 20237.0%

View Redmile Group, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Redmile Group, LLC Q3 2017 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Neoleukin Therapeutics, Inc.July 27, 20232,912,2286.6%
IGM Biosciences, Inc.June 28, 20233,291,0929.9%
MedAvail Holdings, Inc.June 21, 2023124,507,26873.1%
Achilles Therapeutics plcFebruary 14, 20231,608,0893.9%
Kymera Therapeutics, Inc.February 14, 20232,673,8374.9%
Old Ayala, IncSold outFebruary 08, 202300.0%
Zymeworks Inc.August 08, 20225,758,2419.9%
Science 37 Holdings, Inc.June 15, 202219,808,23417.1%
Allakos Inc.February 14, 20222,077,8753.8%
Aprea Therapeutics, Inc.Sold outFebruary 14, 202200.0%

View Redmile Group, LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-01
42024-04-01
42024-03-25
SC 13D/A2024-03-25
42024-03-19
42024-03-14
42024-03-13
SC 13D/A2024-03-13
42024-03-05
SC 13D/A2024-03-05

View Redmile Group, LLC's complete filings history.

Compare quarters

Export Redmile Group, LLC's holdings